Valeant Accused of Bungling Marketing of Female Libido Drug

Valeant Accused of Bungling Marketing of Female Libido Drug


Valeant Pharmaceuticals International Inc. was sued by former investors of Sprout Pharmaceuticals Inc. over claims the company bungled the marketing of a female libido pill it acquired from Sprout in a $1 billion buyout of the drugmaker last year. The lawsuit filed Wednesday claims Valeant violated terms of the deal by overcharging for Addyi and failed to make promised investments to market the drug, designed to bolster women's sex drives.



from Biotech News